EN001

DRUG5 trials

Sponsors

ENCell

Conditions

Charcot-Marie-Tooth Disease Type 1ACharcot-Marie-Tooth Disease, Type IADuchenne Muscular DystrophySarcopenia

Phase 1

Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A

CompletedNCT05333406

ENCellCharcot-Marie-Tooth Disease, Type IA

Start: 2022-02-22End: 2022-12-20Updated: 2023-02-17

Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)

CompletedNCT05338099

ENCellDuchenne Muscular Dystrophy

Start: 2022-01-18End: 2022-12-28Updated: 2024-08-30

Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy

Not yet recruitingNCT06328725

ENCellDuchenne Muscular Dystrophy

Start: 2024-03-31End: 2025-11-30Target: 88Updated: 2024-03-25

Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)

RecruitingNCT06328712

ENCellCharcot-Marie-Tooth Disease Type 1A

Start: 2024-05-30End: 2026-12-31Target: 27Updated: 2026-05-26

Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia

Not yet recruitingNCT07808905

ENCellSarcopenia

Start: 2027-03-01End: 2029-10-31Target: 132Updated: 2026-09-11